VNRX Fail-to-Deliver

Volitionrx Ltd (VNRX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $7.5M, listed on AMEX, employing roughly 75 people, carrying a beta of 1.04 to the broader market. VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. Led by Cameron Reynolds, public since 2012-03-02.

Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.

Latest Date
2026-06-10
Latest FTD Quantity
1.3K
Latest Price
$1.36
30-Day Avg FTD
39.4K
30-Day Total FTD
1.2M

Showing 30 days of SEC fail-to-deliver data for Volitionrx Ltd.

Learn how fails-to-deliver is reported and how to read the data →

Frequently asked VNRX fail to deliver questions

What is the latest VNRX fail-to-deliver count?
As of Jun 10, 2026, Volitionrx Ltd (VNRX) fail-to-deliver quantity is 1.3K shares, with a 30-day average of 39.4K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
What is the FTD aggregate net balance?
FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
How do VNRX FTDs affect options pricing?
Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.